Marcello Laurenti

Mr. Marcello Laurenti


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 April 2020 in JCI Insight
Verified
Journal Article
Open access
PDF file
MLMarcello Laurenti
Marcello Laurenti
Chiara Dalla ManChiara Dalla Man
Chiara Dalla Man
RVRon T Varghese
Ron T Varghese
JAJames C. Andrews
James C. Andrews
RRRobert A. Rizza
Robert A. Rizza
AVAdrian Vella
Adrian Vella
BACKGROUND: Metabolic disorders such as type 2 diabetes have been associated with a decrease in insulin pulse frequency and amplitude. We hypothesized that the T allele at rs7903146 in TCF7L2, previously associated with β cell dysfunction, would be associated with changes in these insulin pulse characteristics. METHODS: Twenty-nine nondiabetic subjects (age 46 ± 2, BMI 28 ± 1 kg/m 2 ) participated in this study. Of these, 16 were homozygous for the C allele at rs7903146 and 13 were homozygous for the T allele. Deconvolution of peripheral C-peptide concentrations allowed the reconstruction of portal insulin secretion over time. These data were used for subsequent analyses. Pulse orderliness was assessed by approximate entropy (ApEn), and the dispersion of insulin pulses was measured by a frequency dispersion index (FDI) after a Fast Fourier Transform (FFT) of individual insulin secretion rates. RESULTS: During fasting conditions, the CC genotype group exhibited decreased pulse disorderliness compared with the TT genotype group (1.10 ± 0.03 vs. 1.19 ± 0.04, P = 0.03). FDI decreased in response to hyperglycemia in the CC genotype group, perhaps reflecting less entrainment of insulin secretion during fasting. CONCLUSION: Diabetes-associated variation in TCF7L2 is associated with decreased orderliness and pulse dispersion, unchanged by hyperglycemia. Quantification of ApEn and FDI could represent novel markers of β cell health. FUNDING: This work was funded by US NIH (DK78646, DK116231), University of Padova research grant CPDA145405, and Mayo Clinic General Clinical Research Center (UL1 TR000135).


22 June 2021 in Metabolites
Verified
Journal Article
Open access
PDF file
MLMarcello Laurenti
Marcello Laurenti
AMAleksey Matveyenko
Aleksey Matveyenko
AVAdrian Vella
Adrian Vella
Pancreatic β-cells are responsible for the synthesis and exocytosis of insulin in response to an increase in circulating glucose. Insulin secretion occurs in a pulsatile manner, with oscillatory pulses superimposed on a basal secretion rate. Insulin pulses are a marker of β-cell health, and secretory parameters, such as pulse amplitude, time interval and frequency distribution, are impaired in obesity, aging and type 2 diabetes. In this review, we detail the mechanisms of insulin production and β-cell synchronization that regulate pulsatile insulin secretion, and we discuss the challenges to consider when measuring fast oscillatory secretion in vivo. These include the anatomical difficulties of measuring portal vein insulin noninvasively in humans before the hormone is extracted by the liver and quickly removed from the circulation. Peripheral concentrations of insulin or C-peptide, a peptide cosecreted with insulin, can be used to estimate their secretion profile, but mathematical deconvolution is required. Parametric and nonparametric approaches to the deconvolution problem are evaluated, alongside the assumptions and trade-offs required for their application in the quantification of unknown insulin secretory rates from known peripheral concentrations. Finally, we discuss the therapeutical implication of targeting impaired pulsatile secretion and its diagnostic value as an early indicator of β-cell stress.

15 November 2023 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
AWAndrew A. Welch
Andrew A. Welch
RFRahele A. Farahani
Rahele A. Farahani
AEAoife Egan
Aoife Egan
MLMarcello Laurenti
Marcello Laurenti
MZMaya Zeini
Maya Zeini
AVAdrian Vella
Adrian Vella
BACKGROUND. Proglucagon can be processed to glucagon-like peptide1 (GLP-1) within the islet, but its contribution to islet function in humans remains unknown. We sought to understand whether pancreatic GLP-1 alters islet function in humans and whether this is affected by type 2 diabetes. METHODS. We therefore studied individuals with and without type 2 diabetes on two occasions in random order. On one occasion, exendin 9-39, a competitive antagonist of the GLP-1 Receptor (GLP1R), was infused, while on the other, saline was infused. The tracer dilution technique ([3-3H] glucose) was used to measure glucose turnover during fasting and during a hyperglycemic clamp. RESULTS. Exendin 9-39 increased fasting glucose concentrations; fasting islet hormone concentrations were unchanged, but inappropriate for the higher fasting glucose observed. In people with type 2 diabetes, fasting glucagon concentrations were markedly elevated and persisted despite hyperglycemia. This impaired suppression of endogenous glucose production by hyperglycemia. CONCLUSION. These data show that GLP1R blockade impairs islet function, implying that intra-islet GLP1R activation alters islet responses to glucose and does so to a greater degree in people with type 2 diabetes. TRIAL REGISTRATION. This study was registered at ClinicalTrials.gov NCT04466618. FUNDING. The study was primarily funded by NIH NIDDK DK126206. AV is supported by DK78646, DK116231 and DK126206. CDM was supported by MIUR (Italian Minister for Education) under the initiative “Departments of Excellence” (Law 232/2016).

29 March 2023 in IEEE Transactions on Biomedical Engineering
Verified
Journal Article
Open access
EFEdoardo Faggionato
Edoardo Faggionato
MLMarcello Laurenti
Marcello Laurenti
AVAdrian Vella
Adrian Vella
Chiara Dalla ManChiara Dalla Man
Chiara Dalla Man
Objective : To date, the lack of a model of glucagon kinetics precluded the possibility of estimating and studying glucagon secretion in vivo , e.g., using deconvolution, as done for other hormones like insulin and C-peptide. Here, we used a nonlinear mixed effects technique to develop a robust population model of glucagon kinetics, able to describe both the typical population kinetics (TPK) and the between-subject variability (BSV), and relate this last to easily measurable subject characteristics. Methods : Thirty-four models of increasing complexity (variably including covariates and correlations among random effects) were identified on glucagon profiles obtained from 53 healthy subjects, who received a constant infusion of somatostatin to suppress endogenous glucagon production, followed by a continuous infusion of glucagon (65 ng/kg/min). Model selection was performed based on its ability to fit the data, provide precise parameter estimates, and parsimony criteria. Results : A two-compartment model was the most parsimonious. The model was able to accurately describe both the TPK and the BSV of model parameters as function of body mass and body surface area. Parameters were precisely estimated, with central volume of distribution V1 = 5.46 L and peripheral volume of distribution V2 = 5.51 L. The introduction of covariates resulted in a significant shrinkage of the unexplained BSV and considerably improved the model fit. Conclusion : We developed a robust population model of glucagon kinetics. Significance : This model provides a deeper understanding of glucagon kinetics and is usable to estimate glucagon secretion in vivo by deconvolution of plasma glucagon concentration data.

1 August 2023 in American Journal of Physiology-Endocrinology and Metabolism
Verified
Journal Article
Closed access
DWDaniel Schembri Wismayer
Daniel Schembri Wismayer
MLMarcello Laurenti
Marcello Laurenti
YSYilin Song
Yilin Song
AEAoife M. Egan
Aoife M. Egan
AWAndrew A. Welch
Andrew A. Welch
AVAdrian Vella
Adrian Vella
This experiment studied the effect of changes in overnight concentrations of free fatty acids (FFAs) and glucose on β-cell function and glucose metabolism. In response to elevation of these metabolites, the dynamic component of the β-cell response to glucose was impaired. This suggests that in health overnight hyperglycemia and FFA elevation can deplete preformed insulin granules in the β-cell.